Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: Results of long-term follow-up Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Ovarian Neoplasms

abstract

  • Prolonged overall survival was observed in patients with no gross residual disease at the time of IP chemotherapy initiation. When compared with similarly treated stage IIIC patients, stage IV patients with malignant pleural effusions appear to have a better outcome than those with other sites of metastasis. Future prospective trials should evaluate the use of IP therapy for patients with stage IV EOC by virtue of malignant pleural effusions only who responded to initial systemic therapy.

publication date

  • June 15, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.23485

PubMed ID

  • 18428210

Additional Document Info

start page

  • 2690

end page

  • 7

volume

  • 112

number

  • 12